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Abstract
Purpose The control of nausea and vomiting induced by
chemotherapy is paramount for overall treatment success in
cancer patients. Antiemetic therapy during chemotherapy in
lymphoma patients generally consists of anti-serotoninergic
drugs and dexamethasone. The aim of this trial was to evaluate
the efficacy of a single dose of palonosetron, a second-
generation serotonin type 3 (5-HT3) receptor antagonist, in
patients with aggressive non-Hodgkin"s lymphoma receiving
moderately emetogenic chemotherapy (MEC) containing
steroids.
Methods Patients received a single intravenous bolus of
palonosetron (0.25 mg) before administration of chemo-
therapy. Complete response (CR) defined as no vomiting
and no rescue therapy during overall phase (0–120 h)
was the primary endpoint. Complete control (CC)
defined as CR and only mild nausea was a secondary
endpoint.
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DOI 10.1007/s00520-010-0974-yResults Eighty-six evaluable patients entered in the study.
A CR was observed in 74 patients (86.0%) during the
overall phase; the CR during the acute (0–24 h) and
delayed (24–120 h) phases was 90.7% and 88.4%,
respectively. CC was 89.5% during the acute and 84.9%
during the delayed phase; the overall CC was 82.6%.
Conclusions This was the first trial, which demonstrated
the efficacy of a single dose of palonosetron in control
CINV in patients with aggressive non-Hodgkin’sl y m p h o m a
receiving MEC regimen containing steroids.
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Introduction
Although chemotherapy-induced nausea and vomiting
(CINV) are not life-threatening adverse events, they can
nevertheless adversely affect the quality of life, and thus
control of CINV plays a key role in the treatment of cancer
patients undergoing chemotherapy. Antiemetic guidelines
[1–3] have defined the emetic risk of antineoplastic agents
[4] as high (>90% emetic risk), moderate (30–90%), low
(10–30%), and minimal (<10%), the figures in parentheses
representing the percentage of patients having emetic
episode(s) when no prophylactic antiemetic protection
provided. CINV prophylaxis for highly emetogenic chemo-
therapy (HEC) includes a three-drug regimen: a 5-HT3
receptor antagonist (5-HT3RA), dexamethasone and a
neurokinin-1 (NK-1) receptor antagonist; for moderately
emetogenic chemotherapy (MEC), standard prophylaxis
includes a two-drug regimen: a 5-HT3RA and dexametha-
sone or methyl-prednisone, both given on the day of
chemotherapy, with the administration of either dexameth-
asone or a 5-HT3RA for 3-4 days after treatment. Currently,
standard antiemetic therapy in patients with lymphomas
undergoing MEC is a combination therapy with a 5-HT3RA
and steroids [5].
The first generation 5-HT3RAs (ondansetron, granisetron,
dolasetron, and tropisetron) have demonstrated considerable
efficacy in preventing acute (0–24 h after chemotherapy)
CINV which is mostly serotonin related, but there is no
clinical evidence to justify their use beyond 24 h after
chemotherapy for prevention of delayed (24–1 2 0ha f t e r
chemotherapy), in part substance P-related, emesis [6].
Palonosetron is a second-generation 5-HT3RA, and is
approved by FDA for treatment of delayed emesis [7].
The characteristics of palonosetron distinguish it from
other 5-HT3RAs [7, 8]. In particular, it has a prolonged
half-life (∼40 h) and a high binding affinity (approximately
2,500-fold higher than that of serotonin), in addition showing
allosteric interactions and positive cooperativity with the
5-HT3 receptor [9, 10]. The actual role of palonosetron in
comparison with the other available 5-HT3RAs is discussed
controversially in all three main antiemetic guidelines.
There is some evidence that palonosetron may be
superior to first generation 5-HT3RAs in providing
control of both nausea and vomiting in patients undergo-
ing either MEC or HEC [11–15]. Due to its unique
pharmacological characteristics [7–10], palonosetron can
protect patients from CINV during the overall emetic risk
period after chemotherapy (0–120 h), even when
employed without corticosteroids.
The aim of this multicentre, open-label, non-randomized,
phase II study was to evaluate the efficacy and safety of a
single intravenous bolus of palonosetron (0.25 mg) for the
prevention of CINV during 5 days post-chemotherapy in
patients with aggressive non-Hodgkin"s lymphoma (NHL)
treated with anthracycline-containing regimens.
Patients and methods
This study (EudraCT number 2006-003189-33, NCT number
01018758) was conducted according to the Declaration of
Helsinki and Good Clinical Practice guidelines. The study
protocol was approved by local ethics committees, and all
patients gave written informed consent to participate before
study entry. Patients with histologically or cytologically
confirmed aggressive NHL, at any stage, were eligible.
Patients were required to be >18 years of age, with an
Eastern Cooperative Oncology Group performance status
of zero to one and acceptable hepatic and renal functions,
scheduled to receive at least one moderately emetogenic
agent on day 1, according to the modified Hesketh
classification [4, 16]. Patients with diagnosis of Hodgkin"s
lymphoma or leukemia, and candidates for multiple day/
high-dose chemotherapy or bone marrow/peripheral blood
stem cell transplantation were excluded.
Treatment plan
Patients received a single intravenous bolus of palonosetron
(0.25 mg), over 30 s, beginning 30 min before chemotherapy
on day 1. Patients were assessed from day 1 throughout
day 5 after the start of chemotherapy, and the antiemetic
response was evaluated during the acute, delayed and
overall phases, as well on each day.
Patients were followed for safety and tolerability, and
adverse events were considered by the investigator to be
possibly, probably or definitely related to study medication
until the start of the next chemotherapy cycle. Patients were
asked to fill in a diary beginning on day 1 until day 5,
reporting the occurrence and severity of emesis and nausea
episodes, as well as the use of rescue medication. At the
1506 Support Care Cancer (2011) 19:1505–1510end of the study, patient global satisfaction with antiemetic
therapy was measured using a visual analogue scale (VAS).
After chemotherapy, rescue medication including dexa-
methasone and/or metoclopramide for nausea and vomiting
was permitted upon request of the patient and recorded in
patient"s diary.
Study endpoints and assessments
The primary endpoint was the overall rate of patients
achieving a complete response (CR), defined as no emetic
episodes and no use of rescue medication during the overall
phase. Secondary endpoints were evaluated during the
acute, delayed and overall phases and included CR rate
during the acute and delayed phases, rate of complete
control (CC; defined as CR with a maximum grade of mild
nausea), percentage of patients experiencing emesis and
nausea (severity graded according to Likert scale), patient
global satisfaction with antiemetic therapy, as measured by
VAS, and safety profile of palonosetron. Severity of nausea
was graded according to Likert scale: 0-none, 1-mild;
2-moderate; 3-severe, according to subjective assessment
by each patient.
Statistical analysis
The efficacy of palonosetron was evaluated upon a one-
stage Fleming study design for determination of response
rates based on a single treatment group [17].
A sample size of 77 patients was estimated using the
exact method (binomial) and assuming that π=20 (null
hypothesis) is the largest value for the proportion of
responders for which the treatment is considered ineffec-
tive, and π=35 (alternative hypothesis) the smallest value
for the proportion of responders for which the treatment is
considered effective, with a probability of type 1 error
equal to 0.05 (one-tail), and a power of 90%. Eighty-five
patients were planned for enrolment, considering a loss of
10% (lost to follow-up, withdrawal of informed consent,
administrative reasons). The safety cohort included all
patients who received at least one dose of the study
medication after registration.
Results
Between June 2006 and July 2008, a total of 91 patients
with NHL were prospectively recruited by ten Italian
centers belonging to the Gruppo Italiano per lo Studio dei
Linfomi (GISL). Five patients were considered not
eligible: four were low grade NHL and one patient had
an ECOG=3. Demographic and baseline data of the 86
evaluable patients are shown in Table 1.T h em a j o r i t yo f
patients had diffuse large B cell lymphoma (77.9%), stage
III and IV disease (67.4%) and received CHOP+/−R
(cyclophosphamide, doxorubicin, vincristine and predni-
sone, ± rituximab) chemotherapy (74.4%).
Efficacy
Regarding the primary endpoint, CR was observed in 74 of
86 patients (86.0%) during the overall phase. CR during
the acute and delayed phases was 90.7% and 88.4%
(Fig. 1), respectively. The CC was 89.5% during the acute
and 84.9% during the delayed phase was; the overall CC
was 82.6% (Table 2). Table 2 shows the proportion of
patients who did not experience both emesis and nausea,
during the delayed and overall phases and on individual
Table 1 Patient characteristics
Characteristic Population (N=86)
N (%)
Age (years)
Median 65
Range 20–87
Male gender 47 (54.6)
ECOG performance status
0–1 57 (66.3)
2 29 (33.7)
Histology
DLBCL 67 (77.9)
FL grade III 8 (9.3)
PTCL 3 (3.5)
ALCL 3 (3.5)
MCL 2 (2.3)
MZL 2 (2.3)
BL 1 (1.2)
Stage
I 12 (14.0)
II 16 (18.6)
III 29 (33.7)
IV 29 (33.7)
Chemotherapy regimen
R-CHOP 40 (46.5)
CHOP 24 (27.9)
R-COMP 13 (15.1)
Other
a 9 (10.5)
DLBCL diffuse large B cell lymphoma, FL follicular lymphoma,
PTCL peripheral T cell lymphoma, ALCL anaplastic large cell
lymphoma, MCL mantle cell lymphoma, MZL marginal zone
lymphoma, BL Burkitt"s lymphoma, CHOP cyclophosphamide,
doxorubicin, vincristine, prednisone, R-CHOP rituximab, cyclophos-
phamide, doxorubicin, vincristine, prednisone, R-COMP rituximab,
cyclophosphamide, vincristine, liposomal doxorubicin, prednisone
aDoxorubicin based regimen
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was 88.4%, while the nausea-free rate was 74.4%; no
patient experienced severe nausea. The median patient
global satisfaction with antiemetic therapy was 8.0 (range,
1–10).
Tolerability
Palonosetron was well tolerated and no patient experienced
a severe adverse event. The most common grade 1–2
adverse events were constipation (7.0%), headache
(5.8%), asthenia (7.0%) and dizziness (1.2%). No grade
3 and 4 adverse events and no significant changes in
laboratory tests or vital signs were observed during the
study period.
Discussion
The results of this multicentre clinical trial demonstrate
that a single dose of palonosetron (0.25 mg) before
chemotherapy, without supplementing with additional
dexamethasone, is effective and well tolerated by patients
with aggressive NHL treated with MEC. Uncontrolled
emesis associated with chemotherapy is sometimes such a
negative experience that it may even lead to refusal by the
patient to undergo potentially life-saving treatments for
their malignancy [18, 19]. Currently, antiemetic guidelines
[1–3] for MEC suggest the use of a 5-HT3RA and
dexamethasone on day 1, followed by dexamethasone on
d a y s2a n d3t op r e v e n td e l a y e dC I N V .T h i sr e c o m m e n -
dation stems from clinical evidence showing that cortico-
steroids increase the effect of other antiemetics [20]s u c h
as low-dose and high-dose metoclopramide [21], first
generation 5-HT3RAs [22, 23], and a NK-1 receptor
antagonist [24, 25]. Clinicians, however, have some
concerns about the use of dexamethasone in clinical
practice because of its potential side effects [5]. Palonose-
tron, due to its unique pharmacological characteristics
[6–10], may be of benefit in avoiding or minimizing the
use of steroids [26, 27].
Two previous studies have assessed the efficacy of first
generation 5-HT3RA (ondansetron and granisetron) in
malignant lymphoma patients undergoing CHOP like
chemotherapy: one study [28] compared ondansetron and
metoclopramide, while Numbenjapon et al. compared
granisetron (GRAN) and metoclopramide [29], both
combined with corticosteroid (CS). Antiemetic prophylaxis
in the OND study was: OND 8 mg/methylprednisolone
80 mg i.v. before chemotherapy and OND 8 mg p.o. after
8 h and at bedtime. OND 8 mg tid days 2–3, and 8 mg tid
prn days 4–5, and prednisolone 75–100 mg qds days 2–5.
In the acute phase, no emesis was registered in 92%, and
no nausea in 79% of the OND/CS-treated group. The
ultimate aim—neither nausea nor emesis—was reached in
77% of OND/CS-treated patients. The control of delayed
nausea was obtained in 81% of patients [28]. Antiemetic
prophylaxis in the Numbenjapon study [29] was GRAN
1 mg with 8 mg dexamethasone before chemotherapy and
Fig. 1 Complete response rate during the overall (0–120 h), acute
(0–24 h), and delayed (24–120 h) phases
Table 2 Emesis-free and nausea-free rates during individual days, the
delayed (24–120 h) and overall phases (0–120 h) and complete control
during the acute (0–24 h), delayed and overall phases
Population (N=86)
N (%)
Emesis free
a
Day 1 79 (91.9)
Day 2 79 (91.9)
Day 3 83 (96.5)
Day 4 86 (100)
Day 5 84 (97.7)
Delayed phase 77 (89.5)
Overall study period 76 (88.4)
Nausea free
b
Day 1 73 (84.9)
Day 2 70 (81.4)
Day 3 77 (89.5)
Day 4 82 (95.3)
Day 5 82 (95.3)
Delayed phase 65 (75.6)
Overall study period 64 (74.4)
Complete control
c
Acute phase 77 (89.5)
Delayed phase 73 (84.9)
Overall study period 71 (82.6)
aNo episodes of vomiting
bNo episodes of nausea of any grading
cNo vomiting episodes, no use of rescue medication, and no more than
mild nausea
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achieved a control response of 87.5% during the acute
phase and 95.8% during the delayed phase.
In the present trial, most patients were treated with
CHOP+/−R (cyclophosphamide 750 mg/sqm i.v., doxorubi-
cin 50 mg/sqm i.v. and vincristine 1.4 mg/sqm i.v. on day 1,
prednisone 100 mg daily o.s. for 5 days ±/− rituximab
375 mg/sqm i.v. on day 1), which is considered the
standard of care for aggressive NHL patients [30]. With a
similar chemotherapeutic regimen, the GELA (Groupe
d'Etude des Lymphomes de l"Adulte) trial [30], which
assessed the additional of rituximab to the CHOP regimen,
has shown an incidence of nausea and vomiting of any
grade of 40–48%, with 4–8% of grades 3–4. In our trial,
the incidence of nausea of any grade ranged from 4.7% to
18.6%, and the rate of vomiting of any grade ranged from
0% to 8.1% during the 5 days of observation. It is also
worthwhile noting that this population is younger and at a
higher risk of emesis, than that of the GELA trial. The
primary endpoint of our study was reached since 86.0% of
patients achieved a CR during the overall study period.
The secondary endpoints were also met as the percentage
of CC in the acute and late phases was 89.5% and 84.9%,
respectively.
Palonosetron was well tolerated and the incidence and
severity of adverse events were low. The modality of
administration by bolus infusion over 30″, differently than
first generation 5-HT3RAs, allows to reduce the overall
treatment time and the staff costs. Finally, the antiemetic
efficacy being equal, a single dose of palonosetron is
less expensive than several infusions of first generation
antagonists. The weakness of our study is absence of
dexamethasone-containing control arm, but recent ran-
domized trials [31, 32] have investigated if the use of
palonosetron might provide the opportunity to reduce the
total corticosteroid dose with no loss of efficacy in
delayed MEC, in patients receiving chemotherapeutic
regimens which don’t include steroid administration.
Both studies demonstrated that a reduced dexameth-
asone dosing regimen offers high and similar protection
as 3-day dosing, as demonstrated by the equivalent
complete response rates in the 5-day observation interval
[31, 32].
This was the first trial, which demonstrated the
efficacy of a single dose of palonosetron in control
CINV in patients receiving MEC regimen containing
steroids.
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